Press Releases October 1, 2026 08:00 PM

Moderna, Inc. to Join the Nasdaq-100 Index® Beginning October 9, 2026

Moderna to join the Nasdaq-100 Index starting October 9, 2026.

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
MRNA

Moderna, Inc. (Nasdaq: MRNA) will be added to the Nasdaq-100 Index, replacing Warner Bros. Discovery, Inc., effective prior to market open on October 9, 2026. This inclusion reflects Moderna’s growth as one of the largest Nasdaq-listed non-financial companies and positions it among a prestigious group of companies tracked by numerous investment products.

Moderna, Inc. to Join the Nasdaq-100 Index® Beginning October 9, 2026
MRNA
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Moderna, Inc. will be added to the Nasdaq-100 Index on October 9, 2026.
  • The Nasdaq-100 Index includes 100 of the largest Nasdaq-listed non-financial companies and is tracked by over 200 investment products with $800 billion+ in assets under management.
  • Moderna replaces Warner Bros. Discovery, indicating a shift in index composition reflecting market capitalization and sector dynamics.

NEW YORK, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced that Moderna, Inc. (Nasdaq: MRNA) will become a component of the Nasdaq-100 Index® (NDX®) replacing Warner Bros. Discovery, Inc. (Nasdaq: WBD) prior to market open on Friday, October 9, 2026.

For additional information, including notifications on changes to any Nasdaq Indexes, please go to https://indexes.nasdaq.com/

About Nasdaq Global Indexes

Nasdaq Global Indexes is one of the world's leading index providers, offering a comprehensive suite of rules-based benchmarks and indexes. The Nasdaq-100 Index® — which measures the performance of 100 of the largest Nasdaq-listed non-financial companies — is tracked by more than 200 investment products with over $800 billion in assets under management globally. Nasdaq Global Indexes publishes and maintains more than 10,000 indexes across asset classes and geographies.

About Nasdaq

Nasdaq (Nasdaq: NDAQ) is a leading technology platform that powers the world’s economies. We architect the infrastructure of the world’s most modern markets, power the innovation economy, and build trust in the financial system. We empower economic opportunity by designing and deploying advanced technology, data, and intelligence solutions that enable our clients to capture opportunities, navigate risk, and strengthen resilience. To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on X @Nasdaq, or at www.nasdaq.com.

Nasdaq®, Nasdaq-100 Index® and NDX® are registered trademarks of Nasdaq, Inc. The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular financial product or an overall investment strategy. Neither Nasdaq, Inc. nor any of its affiliates makes any recommendation to buy or sell any financial product or any representation about the financial condition of any company or fund. Statements regarding Nasdaq’s proprietary indexes are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

Media Contact
Maximilian Leitenberger
[email protected]

Issuer & Investor Contact
Index Client Services
[email protected]

-NDAQF-


Risks

  • Inclusion in a major index can increase stock volatility due to index fund trading and rebalancing activities.
  • Future performance of Moderna may still be affected by factors such as competitive pressures in the biotechnology and pharmaceutical sectors, regulatory approvals, and market conditions.
  • Macroeconomic or sector-specific risks impacting the healthcare and biotechnology industries could influence Moderna's stock despite index inclusion.

More from Press Releases

Sachem Capital Reports Third Quarter 2026 Results Nov 16, 2026 Inter&Co Delivers Record 3Q26 Net Income of US$76.1 Million, With Strong Growth, Higher Margin and Better Efficiency Nov 12, 2026 Super League to Report Third Quarter 2026 Financial Results on Monday, November 16, 2026 Nov 12, 2026 UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights Nov 4, 2026 BioVie Announces Pricing of $4.74 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules Nov 4, 2026